# BPC-157 TB-500: The Wolverine Blend, Audited Against the Record

> BPC-157 TB-500 is the Wolverine blend — BPC-157 paired with TB-500. The tendon, angiogenesis, and actin research, scanned against its sources, plus the FDA 503A and WADA access record. Every claim cited.

Two monitored channels, one panel: BPC-157 supplies the cytoprotective, pro-angiogenic signal; TB-500 supplies the cell-migration signal. Every finding here is single-compound, mostly rodent, and logged to its study.

## BPC-157 and TB-500: the two peptides behind the Wolverine blend

BPC-157 TB-500 is the research-community name for a two-peptide tissue-repair pairing marketed as "Wolverine." It is not a single chemical entity, has no CAS number or molecular weight of its own, and is not an approved product anywhere. It pairs two distinct synthetic peptides whose identifiers this terminal logs separately.

BPC-157 and TB-500 are different molecules doing different jobs. BPC-157 — Body Protection Compound 157 — is a 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV, ~1419 Da) derived from a protein found in human gastric juice [1]. It is the cytoprotective, pro-angiogenic channel: it up-regulates VEGFR2 with downstream Akt-eNOS activation and accelerates blood-flow recovery in ischemic rat muscle [2]. TB-500 is the synthetic N-acetylated heptapeptide Ac-LKKTETQ (~889 Da), corresponding to residues 17-23 of Thymosin Beta-4 [5]. Its LKKTETQ motif binds monomeric G-actin 1:1 and sequesters it by capping both ends, regulating the cytoskeletal dynamics that drive cell migration [3]. The blend reads these as two complementary, largely non-overlapping channels.

The console flags the gap in the same breath. No controlled study has tested the two together, and a 2025 systematic review of BPC-157 in orthopaedic sports medicine — 36 studies, only one in humans — recorded "no clinical safety data" and makes no mention of TB-500 or any combination [6]. This site is a verification terminal, not a clinic and not a vendor. It tags every finding to the constituent it came from, flags every blend-level claim that the record does not support, and reads the [Wolverine legal status and FDA 503A category](/legal-status) before anything else.

## BPC 157 TB 500 at a glance

BPC 157 TB 500 — the unpunctuated form of the same pairing — is two peptides with two independently characterized mechanisms read on one panel. BPC-157 is the cytoprotective, pro-angiogenic channel; TB-500 is the cytoskeletal, cell-migration channel. The pairing is framed as "two complementary modules, one repair signal," which is the basis of the "synergy" claim.

That synergy is a theoretical extrapolation, not a measured result. The structural and signaling facts for each peptide are well attested individually [2][3]; the combined effect is an inference from two separate mechanisms, and no peer-reviewed study defines a synergy ratio, dose, or endpoint for the two given together [6]. The [BPC-157 and TB-500 mechanisms](/research) page sets the two channels out in full.

## Why the BPC-157 TB-500 stack is discussed together

The BPC-157 TB-500 stack is a two-peptide tissue-repair pairing, not an approved medicine. Commercial "Wolverine" vials are commonly labeled with a combined per-vial mass — for example ~10 mg BPC-157 + ~10 mg TB-500 — but no standardized composition or ratio is clinically validated, and the actual BPC-157:TB-500 ratio in unregulated material is not guaranteed [1].

A second identity caveat compounds the first. "TB-500" as sold is the Ac-LKKTETQ heptapeptide (~889 Da), but the overwhelming majority of efficacy data attributed to it were generated with full-length Thymosin Beta-4 (~4963 Da) [4][5]. The stack inherits that gap for one of its two channels. The reason the two are discussed together is the complementary-mechanism rationale, examined in full on the page covering [BPC-157 TB-500 benefits and combination rationale](/benefits).

## What the 'Wolverine' peptide name refers to

The "wolverine peptide" term is high-volume but conflated with the comic-book character, so this terminal treats it strictly as a disambiguation. Here it denotes the BPC-157 + TB-500 research blend — nothing more.

---

A verification terminal for the BPC-157 TB-500 blend — each constituent finding scanned against its own study, the combination link flagged UNVERIFIED, and the FDA 503A access record read before anything else; no clinic behind the console and nothing here dispensed.